In vitro cytotoxic activity of compounds 1, 2, 4a, and 4d against HEK293, SKOV3, LOVO, HT29, MCF-7, and HEPG2 cell lines.
| Compound | IC50a (μM) | |||||
|---|---|---|---|---|---|---|
| HEK293 | SKOV3 | LOVO | HT29 | MCF-7 | HEPG2 | |
| 1 | 0.51 ± 0.02 | 0.14 ± 0.01 | 0.14 ± 0.01 | 0.25 ± 0.08 | 0.26 ± 0.02 | 0.52 ± 0.04 |
| 2 | 7.4 ± 1.15 | 1.22 ± 0.12 | — | — | — | — |
| 4a | 24.61 ± 1.47 | 6.22 ± 0.05 | 3.95 ± 0.38 | 11.88 ± 0.05 | 7.2 ± 1.47 | 13.70 ± 0.66 |
| 4d | 11.07 ± 0.97 | 2.23 ± 0.05 | 2.19 ± 0.38 | 9.00 ± 1.22 | — | — |
| Cisplatinb | 2.12 ± 0.13 | 0.57 ± 0.13 | 0.95 ± 0.13 | 2.19 ± 0.06 | 1.71 ± 0.09 | 2.06 ± 0.11 |
a
IC50 values were calculated from two independent experiments. The values were calculated using Graphpad Prism 5 and reported as the mean ± SD.
b
Cisplatin is a positive control anticancer drug.